{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T07:42:29Z","timestamp":1795246949432,"version":"4.10.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":303,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002619","name":"Ajou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2022.100687","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T02:59:07Z","timestamp":1667617147000},"page":"100687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Impact of Area Under the Concentration-Time Curve-Guided Monitoring on Vancomycin Nephrotoxicity and Treatment Outcomes in Methicillin-Resistant Staphylococcus Aureus Bacteremia in Korean Patients"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-4440","authenticated-orcid":false,"given":"Young Rong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Jin","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yeon","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sae","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-0497","authenticated-orcid":false,"given":"Eun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2022.100687_bib0001","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/cid\/ciz467","article-title":"60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin","volume":"70","author":"Rodvold","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.curtheres.2022.100687_bib0002","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/phar.1382","article-title":"Vancomycin: over 50 years later and still a work in progress","volume":"33","author":"Rybak","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2022.100687_bib0003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2022.100687_bib0005","first-page":"61","article-title":"Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2022.100687_bib0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13104-016-2252-7","article-title":"The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis","volume":"9","author":"Tongsai","year":"2016","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.curtheres.2022.100687_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0008","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.curtheres.2022.100687_bib0009","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cmi.2019.10.029","article-title":"Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity","volume":"26","author":"Dalton","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.curtheres.2022.100687_bib0010","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.curtheres.2022.100687_bib0012","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0013","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ijantimicag.2015.09.010","article-title":"Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"46","author":"Song","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.curtheres.2022.100687_bib0014","first-page":"62","article-title":"Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.curtheres.2022.100687_bib0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0016","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0017","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.curtheres.2022.100687_bib0018","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.curtheres.2022.100687_bib0020","first-page":"408","article-title":"Low Correlation Between Vancomycin Area Under the Curve Over 24 Hours to the MIC (AUC\/MIC ratio) and the Trough Concentration at Steady State in Methicillin-Resistant Staphylococcus Aureus Pneumonia","volume":"37","author":"Sohn","year":"2020","journal-title":"Journal of Korean Society of Health-System Pharmacists"},{"key":"10.1016\/j.curtheres.2022.100687_bib0021","doi-asserted-by":"crossref","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.curtheres.2022.100687_bib0022","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment","volume":"21","author":"Hassoun","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.curtheres.2022.100687_bib0024","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","article-title":"Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"10.1016\/j.curtheres.2022.100687_bib0025","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"57","author":"Moise","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.curtheres.2022.100687_bib0026","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.curtheres.2022.100687_bib0027","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","article-title":"Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial","volume":"44","author":"Al-Sulaiti","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.curtheres.2022.100687_bib0028","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/phar.2191","article-title":"Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients","volume":"38","author":"Turner","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.curtheres.2022.100687_bib0029","first-page":"62","article-title":"Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T01:00:05Z","timestamp":1757898005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X22000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":29,"alternative-id":["S0011393X22000261"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100687","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Area Under the Concentration-Time Curve-Guided Monitoring on Vancomycin Nephrotoxicity and Treatment Outcomes in Methicillin-Resistant Staphylococcus Aureus Bacteremia in Korean Patients","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100687"}}